China’s State Council Unveils “15th Five-Year” National Health Plan with Strong Support for Innovative Therapeutics and AI Integration
China’s State Council has issued the “15th Five-Year” National Health Plan, outlining an ambitious roadmap...
Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the Investigational New Drug (IND) application...
China’s NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines
China’s National Healthcare Security Administration (NHSA) announced the completion of its preliminary formal review for...
B&K Corporation Completes Patient Enrollment in Phase II Diabetic Foot Ulcer Trial for Pro-101-2 rhPDGF-BB Therapy
B&K Corporation Limited (HKG: 2396) announced the completion of patient enrollment in its Phase II...
Huadong Medicine’s Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment
Huadong Medicine Co., Ltd. (SHE: 000963) announced that the clinical trial application for DR10624 injection,...
Hengrui Pharmaceuticals Secures NMPA Clinical Trial Approval for SHR-3079 in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that SHR-3079 injection has received...
Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its Category 1 chemical...
Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC
Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced a global licensing agreement with AstraZeneca plc (NYSE:...
GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures
GlaxoSmithKline plc (GSK) (NYSE: GSK) has formally terminated its neurodegenerative disease research collaboration with Alector,...
Fosun Pharma Secures NMPA Approval for Phase 1 Trial of HLX37 Bispecific Antibody in Combination Therapies for Advanced Solid Tumors
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that China’s National Medical...
Zhaoke Ophthalmology Acquires Global Rights to NVK002 for Myopia Control, Licenses U.S. Rights to Nevakar
Zhaoke Ophthalmology Limited (HKG: 6622) announced the acquisition of global ownership of all intellectual property,...
Haisco Submits NMPA Marketing Application for Crisugabalin’s New Indication in Neuropathic Pain Treatment
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that it has submitted a marketing application...
Shenyang Xingqi Pharmaceutical Secures NMPA Approval for SQ-23101 Injection – Novel Bispecific Antibody Therapy for Thyroid Eye Disease
Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced that China’s National Medical Products Administration (NMPA)...
Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements
Sisram Medical Ltd. (HKG: 1696) announced that the company has entered into a new sublicense...
Teva Secures Global Rights to Polpharma Biologics’ Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Polpharma Biologics announced a global licensing agreement granting...
EMA CHMP Recommends Revocation of TAVNEOS Marketing Authorization Following Data Integrity Concerns in ADVOCATE Trial
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL Limited announced that the European Medicines...
China’s National Health Commission Launches Comprehensive Continuous Medication Management Framework to Enhance Patient Safety and Healthcare Quality
The National Health Commission (NHC) of the People’s Republic of China issued the Notice on...
Drug Farm Closes First Tranche of $55 Million Series D Financing to Advance First-in-Class Pipeline Across Multiple Therapeutic Areas
Drug Farm announced the closing of the first tranche of its USD 55 million Series...
Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development
Shionogi & Co., Ltd. (TYO: 4507) announced that it has entered into a joint research...
Triastek Secures Strategic Financing to Advance 3D-Printed Oral Peptide Pipeline and Build Shanghai International R&D Center
Triastek (Nanjing) Pharmaceutical Technology Co., Ltd. (“Triastek”) announced the completion of a new strategic financing...